Treatment of prolymphocytic leukemia
- 1 November 1982
- Vol. 50 (9) , 1687-1689
- https://doi.org/10.1002/1097-0142(19821101)50:9<1687::aid-cncr2820500905>3.0.co;2-i
Abstract
Prolymphocytic leukemia is characterized by marked splenomegaly, distinctive cellular morphologic characteristics, and a poor clinical course. Five patients with typical PL were treated systematically with vincristine/prednisone, chlorambucil/prednisone, splenic irradiation, splenectomy, and other chemotherapy regimens. No patient responded to vincristine/prednisone. Two patients responded to chlorambucil/prednisone, and four patients had brief responses to splenic irradiation. Two patients underwent splenectomy, one of whom had a prolonged clinical remission. There were no complete remissions. No other chemotherapy combinations were of value. The median survival was 33 months. Recommendations are made to use chlorambucil/prednisone or splenic irradiation as initial treatment. Splenectomy should be considered in patients refractory to these modalities. The course of PL may be more protracted than originally reported. Cancer 50:1687-1689, 1982.This publication has 7 references indexed in Scilit:
- Cell-Surface Markers in Lymphoproliferative DiseaseNew England Journal of Medicine, 1981
- Prolymphocytic Leukaemia: an Ultrastructural Study of 22 CasesBritish Journal of Haematology, 1980
- COMPLETE REMISSION IN PROLYMPHOCYTIC LEUKAEMIA WITH THE COMBINATION CHEMOTHERAPY—CHOPBritish Journal of Haematology, 1979
- EFFICACY OF DOXORUBICIN IN PROLYMPHOCYTIC LEUKAEMIABritish Journal of Haematology, 1979
- Prolymphocytic leukemia. Clinical, histopathological, and cytochemical observationsCancer, 1978
- Hairy-Cell Leukaemia and Prolymphocytic LeukaemiaClinics in Haematology, 1977
- Prolymphocytic LeukaemiaBritish Journal of Haematology, 1974